Telotristat Ethyl

DRUG8 trials

Conditions

Advanced Neuroendocrine NeoplasmBiliary Tract Cancer (BTC)Cachexia; CancerCarcinoid Heart DiseaseCarcinoid SyndromeDiarrheaHepatic ImpairmentLocally Advanced Neuroendocrine Neoplasm

Phase 1

Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment

CompletedNCT03423446

Lexicon PharmaceuticalsHepatic Impairment

Start: 2017-11-28End: 2018-06-15Updated: 2018-10-15

Phase 2

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

TerminatedNCT03790111

TerSera Therapeutics LLCBiliary Tract Cancer (BTC)

Start: 2019-03-13End: 2022-01-13Updated: 2023-04-19

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

CompletedNCT03910387

Emory UniversityLocally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma +2

Start: 2019-04-17End: 2022-06-29Updated: 2025-12-16

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

WithdrawnNCT04713202

Chandrikha ChandrasekharaCarcinoid Syndrome, Diarrhea, Neuroendocrine Tumors

Start: 2021-03-03End: 2024-02-29Updated: 2023-02-10

Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

WithdrawnNCT04776876

M.D. Anderson Cancer CenterAdvanced Neuroendocrine Neoplasm, Carcinoid Syndrome

Start: 2021-03-01End: 2021-09-02Updated: 2021-09-29

Phase 3

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome

WithdrawnNCT04065165

European Organisation for Research and Treatment of Cancer - EORTCCarcinoid Heart Disease, Small Intestinal NET

Start: 2020-04-30End: 2027-10-31Updated: 2020-02-05

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

Active, not recruitingNCT04810091

M.D. Anderson Cancer CenterLocally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm

Start: 2021-05-18End: 2026-08-03Updated: 2026-03-09

Unknown Phase

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

WithdrawnNCT04034745

Andrew Hendifar, MDCachexia; Cancer, Neuroendocrine Tumors, Pancreatic Cancer

Start: 2020-10-31End: 2023-11-30Updated: 2020-12-30

Related Papers

Telotristat ethyl to promote weight stability in patients with advanced pancreatic cancer.

Journal of Clinical Oncology2025-01-27

A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.

Journal of Clinical Oncology2024-01-20